Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Phase 2
Completed
- Conditions
- Anemia, Hemolytic, AutoimmuneFelty SyndromePurpura, ThrombocytopenicAutoimmune Diseases
- Registration Number
- NCT00010387
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
OBJECTIVES:
I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
- Detailed Description
PROTOCOL OUTLINE: Patients receive high-dose cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) starting on day 10 and continuing until blood counts recover.
Patients are followed at 1, 3, 6, and 12 months and then annually thereafter.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Johns Hopkins Oncology Center
🇺🇸Baltimore, Maryland, United States
Johns Hopkins Oncology Center🇺🇸Baltimore, Maryland, United States